CaRCinOma DeLLa PROstata - Osservatorio Nazionale Screening

ibliografia--Desai A, Wu H, Sun L, et al. Complete embedding and close step-sectioning of radical prostatectomyspecimens both increase detection of extra-prostatic extension, and correlate with increased disease-freesurvival by stage of prostate cancer patients. Prostate Cancer Prostatic Dis 2002; 5: 212-8.--Di Paola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination(PC-SPES) in prostate cancer. N Engl J Med 1998; 339: 785-91.--Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol 2005 Feb; 12Suppl 1:44-8.--Djavan B, Remzi M, Schulman CC, Marberger M, Zlotta AR. Repeat prostate biopsy: who, how and when?a review. Eur Urol 2002; 42: 93-103.--Djavan B, Zlotta A, Schulman C, et al. Chemotherapeutic prevention studies of prostate cancer. J Urol2004; 171: S10-3.--Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospectivestudy of 1,051 men. J Urol 2000; 163: 1144-8.--Dorey G. Men’s health. Restoring pelvic floor function in men: review of RCTs. Br J Nurs 2005; 14:1014 –8.--Doust J, Miller E, Duchesne G, Kitchener M, Weller D. A systematic review of brachytherapy. Is it an effectiveand safe treatment for localised prostate cancer? Aust Fam Physician 2004; 33: 525-9.--Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening:estimates from the European Randomized study of screening for prostate cancer. J Natl Cancer Inst2003; 95: 868-78.--Eastham JA, Riedel E, Scardino PT, et al. Polyp Prevention Trial Study Group. Variation of serum prostatespecificantigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-700.--Eble JN, Sauter G, Epstein JI, Sesterhenn IA. “Tumours of the urinary system and male genital organs”,WHO 2004.--Eggener SE, Roehl KA & Catalona WJ. Predictors of subsequent prostate cancer in men with a prostatespecific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol 2005; 174: 500-4.--Eichler K, Wilby J, Hempel S, Myers L, Kleijnen J. Diagnostic value of systematic biopsy methods in theinvestigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605-12.--Eisenberger MA, Partin AW, Ond C, Roostelaar CV, Epstein J, Walsh PC. Natural history of progression ofpatientswith biochemical (PSA) relapse following radical prostatectomy. Update Proc ASCO 2003; 22: 380.--Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostatecancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002; 12: 2294-302.--Engels FK, Verweij J. Docetaxel administration schedule: from fever to tears? A review of randomised studies.Eur J Cancer 2005; 41: 1117-26.--Enting RH, Oldenmenger WH, Van Der Rijt CC, et al. A prospective study evaluating the response of patientswith unrelieved cancer pain to parenteral opioids. Cancer 2002; 94: 3049-56.--Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee:The 2005-a International Societyof Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.Am J Surg Pathol 2005; 29: 1228-4.--Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radicalprostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005; (216):34-63.--Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod Pathol2004; 17: 307-15.--European Association of Urology. EAU Guidelines on pain management. March 2007.--European Association of Urology. EAU Guidelines on prostate cancer. Update March 2007.--Fadare O, Wang S, Mariappan MR. Practice patterns of clinicians following isolated diagnoses of atypicalsmall acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med 2004; 128: 557-60.--Faden R. e Beauchamp T. A History and a Theory of Informed Consent, Oxford University Press, New-York-Oxford, 1986.131